Market Overview

Morgan Stanley Remains Confident In CIGNA Following Management Visit

Share:
Related CI
Barclays Raises Price Targets On Healthcare Companies
8 Managed Care Stocks Wells Fargo Is Watching
MGIC Downgraded by 2 Notches to Hold on Industry Risks - Analyst Blog (Zacks)

In a report published Wednesday, Morgan Stanley analyst Andrew Schenker reiterated an Overweight rating and $99.00 price target on CIGNA (NYSE: CI).

In the report, Morgan Stanley noted, “Expect continued improvement in Medicare. Cigna may not see the full benefit of some of the triage activities it implemented to improve the Medicare business in 2H13 until 2H14. The measures included identifying underperforming facilities, renegotiating reimbursement rates, and modifying networks where necessary. Recall, the company has not incorporated any improvement in Medicare in its FY14 outlook. In addition, Cigna anticipates an improvement in Medicare margins in FY15 as it continues to enhance networks and products.”

CIGNA closed on Tuesday at $89.12.

Latest Ratings for CI

DateFirmActionFromTo
Mar 2015BarclaysMaintainsEqual-weight
Feb 2015JP MorganMaintainsOverweight
Feb 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for CI
View the Latest Analyst Ratings

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (CI)

Around the Web, We're Loving...